AI Roleplay Is Easy. Building Pharma-Ready AI Practice Is Hard.

Chief Sales Officer "Mark" — Follow His Story

Mark had started asking a different question about launch readiness. Instead of focusing only on whether training was complete, he wanted to know whether representatives could demonstrate the capabilities the business needed before they entered high-stakes HCP conversations. That meant giving the field more opportunities to practice, receive feedback, improve, and demonstrate proficiency.

AI roleplay seemed like an obvious solution. The technology could give every representative access to an HCP conversation whenever they wanted to practice. It could eliminate many of the scheduling and scalability problems associated with traditional roleplay, while giving the organization more visibility into performance. Vendors were appearing everywhere, and nearly every demonstration promised realistic conversations, instant feedback, and AI-powered coaching.

Then Mark asked his medical, legal, regulatory, and learning teams a simple question: What exactly is the AI teaching our representatives? Suddenly, choosing an AI roleplay platform became much more complicated.

A Realistic Conversation Isn't Necessarily a Good Training Experience

Generative AI has made conversational simulation remarkably accessible. Give an AI model a persona, provide some instructions, define a situation, and it can create a convincing conversation within minutes.

For many applications, that may be enough. Pharmaceutical skill development creates a different standard because a conversation can sound authentic while still reinforcing the wrong information, behaviors, or messaging.

Mark's representatives weren't practicing generic sales conversations. They were discussing therapies, clinical evidence, patient populations, efficacy and safety information, competitive considerations, and approved messaging with simulated healthcare professionals. The value of the practice depended on whether the simulation accurately reflected the environment representatives would encounter in the field.

Mark began evaluating AI practice against a more demanding set of questions:

• Does the scenario reflect our actual commercial strategy and field environment?
• Is the HCP persona realistic for the customers our representatives encounter?
• Is the AI grounded in the appropriate product and clinical information?
• Can representatives practice the specific objections they are likely to hear?
• Are we measuring the selling behaviors our organization actually expects?
• Can the system identify questionable or inaccurate statements?
• Does the feedback help representatives improve the skills we are trying to develop?
• Can managers use the resulting data to continue development through coaching?
• Source grounding: Practice should reflect the appropriate product, clinical, study, and organizational information.
• Scenario design: Simulations should reproduce meaningful field situations rather than generic sales conversations.
• Behavior alignment: Evaluation should measure the skills and behaviors the organization has defined as important.
• Accuracy validation: Organizations need visibility into whether learners are using supported information appropriately.
• Feedback quality: Feedback should help learners understand what to change and provide an opportunity to apply it again.
• Governance: AI practice should operate within the organization's broader requirements for responsible technology use.
• Human reinforcement: Managers and learning leaders should be able to use performance insights to continue development beyond the simulation.
• Define: Identify the skills and behaviors required for successful field execution.
• Design: Build realistic scenarios around actual products, customers, objections, and business challenges.
• Ground: Use appropriate source information to create a scientifically relevant practice environment.
• Practice: Give representatives repeated opportunities to apply skills in realistic conversations.
• Validate: Evaluate both behavioral execution and factual accuracy where appropriate.
• Improve: Deliver actionable feedback and allow learners to immediately apply it.
• Coach: Give managers visibility into development needs and performance patterns.
• Measure: Track skill progression across individuals, teams, and the broader field organization.

The technology could generate a conversation. The harder challenge was creating a conversation that was strategically relevant, scientifically grounded, behaviorally meaningful, and appropriate for a regulated environment.

Generic Practice Creates Generic Capability

As Mark tested different approaches, he began to see another limitation. Many AI roleplay experiences were designed to make scenario creation fast and simple. A user could select a persona, describe a sales situation, enter an objective, and begin practicing.

That accessibility had value, but Mark wasn't trying to help his representatives become generally better conversationalists. His organization had specific products, customers, commercial strategies, selling methodologies, competencies, and expectations for field execution.

If a launch required representatives to change physician perceptions around a new study, the simulation needed to recreate that challenge. If the organization wanted representatives to demonstrate a particular questioning strategy, the evaluation needed to measure it. If experienced representatives needed to rebuild trust with an HCP after a negative product experience, the simulated physician needed to behave differently from an amenable customer.

MannKind's progressive roleplay program demonstrated this distinction. Rather than relying on a single generalized conversation, the organization used five Afrezza scenarios with increasing levels of difficulty, a real-time Prescribing Information update simulation, and a full-call FUROSICX scenario. Learners progressed from more amenable physicians toward resistant, trust-rebuilding conversations while receiving behavioral scoring aligned to defined selling competencies.

For Mark, customization wasn't simply about making AI feel more realistic. The scenario itself was part of the instructional design. What representatives practiced determined what capabilities they developed.

In Pharma, Accuracy Becomes Part of the Practice Experience

There was another problem Mark couldn't ignore. Generative AI is designed to generate responses, and even highly capable models can produce information that sounds plausible without being appropriate for a specific pharmaceutical conversation.

That risk works in both directions. The simulated HCP needs to operate within the intended scenario, but the organization also needs visibility into what the representative says during practice.

A representative may confidently misstate a study result, overextend a claim, incorrectly describe a patient population, or introduce information that isn't supported by the materials governing the scenario. Traditional roleplay depends heavily on the facilitator or observer catching those moments.

AI creates an opportunity to make that evaluation more systematic, but only if scientific and factual accuracy are intentionally built into the experience.

In Allergan's MSL onboarding program, new hires completed eight high-fidelity AI simulations covering product discussions and objection handling before certification. The solution incorporated Fact Checker to validate scientific accuracy alongside behavior-level scoring and conversational-efficiency measurement. Trainers could use the resulting data to identify development needs before live evaluation and HCP engagement.

Mark saw the significance immediately. AI wasn't valuable simply because it could pretend to be an HCP. It could also help create another layer of visibility into whether representatives were practicing the conversation accurately as well as effectively.

Responsible AI Requires More Than Guardrails

Mark's organization already had an enterprise conversation underway about responsible AI. Security, privacy, governance, approved use cases, and data handling were all important parts of that discussion.

But skill development introduced another dimension of responsible AI: What behaviors and information are employees repeatedly practicing?

If representatives practice a conversation three, five, or ten times, the experience is doing more than evaluating them. It is reinforcing patterns. Poorly designed practice can reinforce weak behaviors just as effectively as well-designed practice can reinforce strong ones.

That meant Mark couldn't evaluate AI roleplay only as a technology purchase. He had to evaluate it as a capability-development system.

For pharmaceutical organizations, responsible AI practice should consider several interconnected elements:

For Mark, these weren't features to add after choosing an AI tool. They were requirements for determining whether the tool could safely and effectively support pharmaceutical skill development.

The Goal Isn't More Roleplay. It's Better Skill Development.

Once Mark stopped thinking about AI roleplay as a standalone technology, its role in the broader learning strategy became clearer.

The objective wasn't to maximize the number of simulations representatives completed. It was to use practice to improve specific capabilities. That required connecting each simulation to what employees had already learned, the behaviors they were expected to demonstrate, the feedback they received, and the coaching that followed.

The Botox Account Specialist program provided a useful example. Approximately 200 representatives practiced conversations around a new chronic migraine study using a simulated neurologist persona. The experience combined realistic HCP dialogue, defined selling skills, Fact Checker validation against study information, repeated practice, and manager-accessible performance insights. Learners averaged three simulation attempts and demonstrated a 5% improvement in targeted skills within one week.

The result Mark cared about wasn't simply three roleplays per learner. It was the progression those attempts represented. Representatives could practice, receive feedback, make adjustments, and practice again while the organization gathered information about how capability was developing.

That transformed AI roleplay from an isolated practice tool into part of a larger development cycle.

Practice Data Should Make Coaching Better

Mark had already discovered that frontline managers became more valuable when they had better information about where representatives needed help. AI practice could significantly expand that visibility.

Without performance data, a manager may know that a representative completed training and passed certification but still need to observe several customer interactions before identifying a specific development opportunity. Practice data can surface those opportunities earlier.

If several simulations show that a representative struggles to navigate resistance, the manager has a coaching starting point. If another representative consistently communicates the clinical information accurately but misses opportunities to uncover customer needs, coaching can focus on questioning and listening. If an entire team struggles with the same objection, the issue may require broader reinforcement rather than individual intervention.

The technology doesn't replace the manager's judgment. It gives the manager another source of evidence to make coaching more focused and actionable.

This was important to Mark because the organization's goal wasn't to create a separate AI practice ecosystem. Learning, practice, coaching, and measurement needed to reinforce one another.

Mark Changed the Question He Asked About AI

When Mark first explored AI roleplay, he asked the same question many sales leaders were asking: "How can we use AI to give our representatives more opportunities to practice?"

It was still a worthwhile question, but it was incomplete.

After seeing what pharmaceutical-grade practice required, Mark began asking:

"How can we use AI to build the specific capabilities our field needs while protecting the accuracy, consistency, and quality our business requires?"

That changed his evaluation criteria considerably. The best solution wasn't necessarily the one that could generate a scenario fastest or provide the most generic simulations. It was the one that could reproduce the organization's actual performance environment and connect practice to measurable development.

AI made scalable roleplay possible. Strategy, instructional design, source grounding, measurement, and coaching made that roleplay valuable.

From AI Roleplay to AI-Powered Skill Development

The distinction ultimately became simple for Mark. AI roleplay creates a conversation. AI-powered skill development uses that conversation to deliberately build and measure capability.

A stronger model connects several elements:

AI provides the scalability that makes this model possible across large organizations. But the technology is only one part of the solution.

For Mark, that distinction pointed toward an even larger realization. His organization had spent years buying different solutions for learning, content, practice, coaching, and measurement. Yet the business didn't experience those activities separately. It simply needed people who could develop and apply new capabilities quickly enough to keep pace with change.

Key Takeaways

AI is dramatically expanding what's possible for pharmaceutical training and skill development, particularly by making realistic, repeated conversational practice available at scale. But the ability to generate an AI roleplay is becoming increasingly common. The greater challenge is designing practice that reflects the organization's actual products, customers, scientific information, selling behaviors, compliance expectations, and business objectives.

Pharma-ready AI practice requires more than a realistic chatbot. It requires intentionally designed scenarios, appropriate source grounding, meaningful behavioral measurement, accuracy validation, actionable feedback, repeated application, and integration with manager coaching.

For Mark, AI roleplay was no longer the strategy. It was an important component of something much larger: a connected system for continually building the capabilities the field needs to perform.

And that led Mark to the question that would bring the entire journey together: What if pharma doesn't actually have a training problem? What if it has a Skill Agility problem?

Next in Mark's story: Pharma Doesn't Have a Training Problem. It Has a Skill Agility Problem.